Collaborating to advance cancer research: The International Immuno-Oncology Network

May 31, 2017

Bristol Myers Squibb has long believed that innovation in cancer research can be accelerated through collaborative research partnerships. That’s why, in 2012, we formed the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol Myers Squibb and academia that aims to advance Immuno-Oncology (I-O) science through translational medicine to improve patient outcomes.

The II-ON was one of the first networks to bring academia and industry together to further the scientific understanding of I-O. The network has generated cutting-edge data that were helpful in informing the development of new I-O compounds and produced some of the earliest findings on a variety of biomarkers and target identification and validation.

Over the past six years, the II-ON has expanded from 10 to 16 sites and now includes more than 350 investigators working on over 250 projects across 22 tumor types. 

Today, through the II-ON, we are collaborating with leading cancer research institutions around the world to generate innovative I-O science, launch biology-driven trials and seek out cutting-edge technologies with the goal of translating research findings into clinical trials and, ultimately, clinical practice.

RELATED ARTICLES
Advancing Cancer Research through Collaboration
Advancing Cancer Research through Collaboration